ClinicalTrials.gg
CompletedNCT05730192EAGLEUpdated Oct 26, 2026Results posted

EAGLE Trial CADDIE Artificial Intelligence Endoscopy

An interventional study of Colonoscopy with CADDIE and Standard Colonoscopy in Colorectal Cancer, Polyp of Colon and Adenoma Colon, sponsored by Odin Medical. Completed at 8 sites in 4 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Odin Medical (part of Olympus Corporation) · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 26, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
985
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 429 studies in Colorectal Neoplasms with a site in Italy — 103 open to participants now, 143 under way, 18 of them phase 3. Colorectal Neoplasms · Italy.

Enrollment
32nd of 329
985 · median 215
Started
2023
with 24 others
No phase
54 of 429
16 open now
Registered
328th of 429
by date

Among the 429 studies in Colorectal Neoplasms with a site in Italy, this one is the 32nd largest by enrollment of the 329 interventional ones that give a count, is one of 25 that started in 2023, is one of 54 with no phase, and was the 328th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

103 of the 429 studies in Colorectal Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 429 studies in Colorectal Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

The EAGLE study is a prospective randomized controlled multicenter parallel design trial, for the assessment of clinical performance of the CADDIE device and to confirm that the device performs as expected.

Read the detailed description

The EAGLE study will be conducted with a parallel design. Patients who meet the study inclusion/exclusion criteria will be randomized in a 1:1 ratio to receive either computer-aided colonoscopy (CADDIE Arm) using CADDIE or standard colonoscopy without CADe (Control Arm). All resected polyps will be submitted for histologic examination.

03

Conditions studied

  • Colorectal Cancer
  • Polyp of Colon
  • Adenoma Colon

Keywords

  • Screening
  • Surveillance
  • Artificial Intelligence
  • Colonoscopy
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Screening or surveillance colonoscopy
  2. Age 40 years or older

Exclusion criteria

Exclusion Criteria:

  1. Emergency colonoscopies
  2. Inflammatory bowel disease (IBD)
  3. Colorectal Cancer (CRC)
  4. Previous Colorectal Cancer (CRC)
  5. Previous colonic resection
  6. Returning for a planned elective therapeutic colonoscopy.
  7. Polyposis syndromes (familial adenomatous polyposis)
  8. for or polypectomy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
985 participants (actual)

Study arms

  • Experimental
    CADDIE colonoscopy (CADDIE Arm)

    CADDIE is a computer-assisted detection (CADe) device used in conjunction with endoscopy for the detection of abnormal lesions in the gastrointestinal tract.

    Device: Colonoscopy with CADDIE

  • Active comparator
    Standard high-definition white light colonoscopy (Control Arm)

    Patients will receive a standard colonoscopy

    Procedure: Standard Colonoscopy

Interventions

  • DeviceColonoscopy with CADDIE

    A standard colonoscopy is performed with real-time support of the computer-aided detection (CADe) device CADDIE, used to assist the endoscopist in the detection of colorectal lesions.

    Also known as: Colonoscopy

  • ProcedureStandard Colonoscopy

    A standard colonoscopy performed without the assistance of any computer-aided detection (CADe) system. Lesion detection relied solely on the endoscopist's visual assessment and clinical judgment.

06

What researchers measure

Primary outcomes

  1. Adenoma Per Colonoscopy (APC)

    The total number of histologically confirmed adenomas and adenocarcinomas divided by the total number of procedures performed.

    Time frame: During the procedure

  2. Positive Percent Agreement (PPA)

    The percent of histologically confirmed adenomas, sessile serrated adenomas and large (\>10mm) hyperplastic polyps of the proximal colon (cecum, ascending colon, hepatic flexure, and transverse colon) out of total number of resections.

    Time frame: During the procedure

Secondary outcomes

  1. Adenoma Detection Rate (ADR)

    The percentage of examinations with at least one histologically confirmed adenoma or adenocarcinoma divided by total number of procedures performed.

    Time frame: During procedure

  2. Sessile Serrated Adenomas Per Colonoscopy (SSAPC)

    Total number of histologically confirmed sessile serrated adenomas, traditional serrated adenomas, or serrated lesion with cytological dysplasia, excluding hyperplastic polyps, divided by the total number of procedures performed.

    Time frame: During procedure

  3. Sessile Serrated Adenomas Per Colonoscopy* (SSAPC*)

    Total number of histologically confirmed sessile serrated adenomas, with or without cytological dysplasia, divided by the total number of procedures performed.

    Time frame: During procedure

  4. Neoplastic Polyps Per Colonoscopy (NPPC)

    Total number of histologically confirmed adenomas, adenocarcinomas, sessile serrated adenomas, and traditional serrated adenomas divided by the total number of procedures performed.

    Time frame: During procedure

  5. Large Polyps Per Colonoscopy (PPC)

    The total number of histologically confirmed polyps ≥ 10 mm detected (adenomas, adenocarcinomas, sessile serrated adenoma, traditional serrated adenoma, hyperplastic), divided by the total number of colonoscopies.

    Time frame: During procedure

  6. Large Adenoma Per Colonoscopy

    The total number of histologically confirmed ≥ 10 mm adenomas and adenocarcinomas divided by the total number of colonoscopies.

    Time frame: During the procedure

  7. Colonoscope Withdrawal Time of Negative Procedures

    The time it takes to withdraw the colonoscope from the furthest point (TI or caecum) for colonoscopies that did not require any biopsies or resections.

    Time frame: During procedure

  8. Colonoscope Withdrawal Time

    The time it takes to withdraw the colonoscope from the furthest point (TI or cecum) back to the rectum, including biopsy

    Time frame: During procedure

07

Results

Posted Oct 26, 2026

Participant flow

985 patients gave informed consent: 946 patients planned and an additional 39 were recruited to replace patients who did not undergo a colonoscopy procedure, high-risk FIT+ patients, or procedures which used an equipment not cleared for use in the US. 973 patients were randomized (Safety population). 934 eligible patients underwent a complete procedure (ITT). 841 patients reflective of the device's intended use were included in primary analysis (mITT)

Participant flow — Overall Study
MilestoneCADDIE Colonoscopy (CADDIE Arm)Standard High-definition White-light Colonoscopy (SoC Arm)
Started478495
Completed461473
Not completed1722

Outcome measures

PrimaryAdenoma Per Colonoscopy (APC)

The total number of histologically confirmed adenomas and adenocarcinomas divided by the total number of procedures performed.

Time frame:
During the procedure
Reported as:
Mean · Colonoscopies
Adenoma Per Colonoscopy (APC)
ColonoscopiesCADDIE Colonoscopy (CADDIE Arm)Standard Colonoscopy (Control Arm)
Adenoma Per Colonoscopy (APC)0.82 ± 1.400.62 ± 1.19
Statistical analysis
  • CADDIE Colonoscopy (CADDIE Arm) vs Standard Colonoscopy (Control Arm) · Mixed Models Analysis · p = 0.01 · Mean ratio: 1.33 · 95% CI 1.06 to 1.67
PrimaryPositive Percent Agreement (PPA)

The percent of histologically confirmed adenomas, sessile serrated adenomas and large (\>10mm) hyperplastic polyps of the proximal colon (cecum, ascending colon, hepatic flexure, and transverse colon) out of total number of resections.

Time frame:
During the procedure
Reported as:
Count of units · Polyps
Positive Percent Agreement (PPA)
PolypsCADDIE Colonoscopy (CADDIE Arm)Standard Colonoscopy (Control Arm)
Positive Percent Agreement (PPA)377276
Statistical analysis
  • CADDIE Colonoscopy (CADDIE Arm) vs Standard Colonoscopy (Control Arm) · Mixed Models Analysis · Mean difference (final values): 0.5
SecondaryAdenoma Detection Rate (ADR)

The percentage of examinations with at least one histologically confirmed adenoma or adenocarcinoma divided by total number of procedures performed.

Time frame:
During procedure
Reported as:
Count of units · Colonoscopies
Adenoma Detection Rate (ADR)
ColonoscopiesCADDIE Colonoscopy (CADDIE Arm)Standard Colonoscopy (Control Arm)
Adenoma Detection Rate (ADR)180 (0 to 0)152 (0 to 0)
Statistical analysis
  • CADDIE Colonoscopy (CADDIE Arm) vs Standard Colonoscopy (Control Arm) · Mixed Models Analysis · p = 0.03 · Mean difference (final values): 7.3 · 95% CI 0.7 to 13.9
SecondarySessile Serrated Adenomas Per Colonoscopy (SSAPC)

Total number of histologically confirmed sessile serrated adenomas, traditional serrated adenomas, or serrated lesion with cytological dysplasia, excluding hyperplastic polyps, divided by the total number of procedures performed.

Time frame:
During procedure
Reported as:
Mean · Sessile Serrated Adenoma
Sessile Serrated Adenomas Per Colonoscopy (SSAPC)
Sessile Serrated AdenomaCADDIE Colonoscopy (CADDIE Arm)Standard Colonoscopy (Control Arm)
Sessile Serrated Adenomas Per Colonoscopy (SSAPC)0.09 ± 0.460.04 ± 0.21
Statistical analysis
  • CADDIE Colonoscopy (CADDIE Arm) vs Standard Colonoscopy (Control Arm) · Regression, Linear · p = 0.03 · Mean ratio: 2.15 · 95% CI 1.07 to 4.32
SecondarySessile Serrated Adenomas Per Colonoscopy* (SSAPC*)

Total number of histologically confirmed sessile serrated adenomas, with or without cytological dysplasia, divided by the total number of procedures performed.

Time frame:
During procedure
Reported as:
Mean · Sessile Serrated Adenoma
Sessile Serrated Adenomas Per Colonoscopy* (SSAPC*)
Sessile Serrated AdenomaCADDIE Colonoscopy (CADDIE Arm)Standard Colonoscopy (Control Arm)
Sessile Serrated Adenomas Per Colonoscopy* (SSAPC*)0.08 ± 0.450.03 ± 0.16
Statistical analysis
  • CADDIE Colonoscopy (CADDIE Arm) vs Standard Colonoscopy (Control Arm) · Regression, Linear · p = 0.006 · Mean ratio: 3.30 · 95% CI 1.41 to 7.571
SecondaryNeoplastic Polyps Per Colonoscopy (NPPC)

Total number of histologically confirmed adenomas, adenocarcinomas, sessile serrated adenomas, and traditional serrated adenomas divided by the total number of procedures performed.

Time frame:
During procedure
Reported as:
Mean · Adenoma
Neoplastic Polyps Per Colonoscopy (NPPC)
AdenomaCADDIE Colonoscopy (CADDIE Arm)Standard Colonoscopy (Control Arm)
Neoplastic Polyps Per Colonoscopy (NPPC)0.91 ± 1.480.66 ± 1.20
Statistical analysis
  • CADDIE Colonoscopy (CADDIE Arm) vs Standard Colonoscopy (Control Arm) · Regression, Linear · p = 0.002 · Mean ratio: 1.39 · 95% CI 1.12 to 1.73
SecondaryLarge Polyps Per Colonoscopy (PPC)

The total number of histologically confirmed polyps ≥ 10 mm detected (adenomas, adenocarcinomas, sessile serrated adenoma, traditional serrated adenoma, hyperplastic), divided by the total number of colonoscopies.

Time frame:
During procedure
Reported as:
Mean · Large polyps
Large Polyps Per Colonoscopy (PPC)
Large polypsCADDIE Colonoscopy (CADDIE Arm)Standard Colonoscopy (Control Arm)
Large Polyps Per Colonoscopy (PPC)0.12 ± 0.440.05 ± 0.24
Statistical analysis
  • CADDIE Colonoscopy (CADDIE Arm) vs Standard Colonoscopy (Control Arm) · Mixed Models Analysis · p = 0.003 · Mean ratio: 2.36 · 95% CI 1.33 to 4.17
SecondaryLarge Adenoma Per Colonoscopy

The total number of histologically confirmed ≥ 10 mm adenomas and adenocarcinomas divided by the total number of colonoscopies.

Time frame:
During the procedure
Reported as:
Mean · Confirmed adenomas
Large Adenoma Per Colonoscopy
Confirmed adenomasCADDIE Colonoscopy (CADDIE Arm)Standard Colonoscopy (Control Arm)
Large Adenoma Per Colonoscopy0.09 ± 0.360.04 ± 0.23
Statistical analysis
  • CADDIE Colonoscopy (CADDIE Arm) vs Standard Colonoscopy (Control Arm) · Mixed Models Analysis · p = 0.04 · Mean ratio: 1.93 · 95% CI 1.03 to 3.62
SecondaryColonoscope Withdrawal Time of Negative Procedures

The time it takes to withdraw the colonoscope from the furthest point (TI or caecum) for colonoscopies that did not require any biopsies or resections.

Time frame:
During procedure
Reported as:
Median · Minutes
Colonoscope Withdrawal Time of Negative Procedures
MinutesCADDIE Colonoscopy (CADDIE Arm)Standard Colonoscopy (Control Arm)
Colonoscope Withdrawal Time of Negative Procedures8 (7 to 11)8 (7 to 10)
SecondaryColonoscope Withdrawal Time

The time it takes to withdraw the colonoscope from the furthest point (TI or cecum) back to the rectum, including biopsy

Time frame:
During procedure
Reported as:
Median · Minutes
Colonoscope Withdrawal Time
MinutesCADDIE Colonoscopy (CADDIE Arm)Standard Colonoscopy (Control Arm)
Colonoscope Withdrawal Time11 (8 to 15)10 (8 to 13)

Adverse events

Collected over From the start of the procedure up to the follow-up phone call (24 hours post-procedure). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CADDIE Colonoscopy (CADDIE Arm)0/478 (0%)0/478 (0%)2/478 (0.4%)
Standard Colonoscopy (Control Arm)0/495 (0%)0/495 (0%)3/495 (0.6%)
Most frequent other events
Most frequent other events
EventCADDIE Colonoscopy (CADDIE Arm)Standard Colonoscopy (Control Arm)
Abdominal pain related to the procedure,Gastrointestinal disorders1/4782/495
HypoxiaRespiratory, thoracic and mediastinal disorders1/4780/495
Nausea possibly related to the procedureGastrointestinal disorders0/4781/495

Baseline characteristics

985 patients gave informed consent: A total of 946 patients were planned, and an additional 39 were recruited to replace patients who did not undergo a colonoscopy procedure, symptomatic FIT+ patients, and procedures which used an endoscope not cleared. 934 eligible patients completed a screening or surveillance colonoscopy.

Age, Continuous
Age, Continuous(Year)CADDIE Colonoscopy (CADDIE Arm)Standard Colonoscopy (Control Arm)Total
Mean58.7 ± 9.058.2 ± 9.558.5 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)CADDIE Colonoscopy (CADDIE Arm)Standard Colonoscopy (Control Arm)Total
Female194218412
Male223206429
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CADDIE Colonoscopy (CADDIE Arm)Standard Colonoscopy (Control Arm)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White414423837
More than one race000
Unknown or Not Reported303
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CADDIE Colonoscopy (CADDIE Arm)Standard Colonoscopy (Control Arm)Total
Hispanic or Latino7566141
Not Hispanic or Latino337349686
Unknown or Not Reported5914
Colonoscopy indication
Colonoscopy indication(partecipants)CADDIE Colonoscopy (CADDIE Arm)Standard Colonoscopy (Control Arm)Total
Screening colonoscopy324329653
Surveillance colonoscopy9395188
08

Study locations

8 sites
  • Sana Klinikum Lichtenberg
    Berlin, Germany
  • Humanitas Mater Domini
    Castellanza, Varese 21100, Italy
  • Humanitas Catania
    Catania, 95045, Italy
  • Humanitas Research Hospital
    Milan, 20089, Italy
  • H-T. Centrum Medyczne
    Tychy, 43-100, Poland
  • The Maria Sklodowska-Curie National Research Institute of Oncology
    Warsaw, 00-001, Poland
  • Przychodnia Polskiej Fundacji Gastroenterologii
    Warsaw, 00-631, Poland
  • University Hospital "Clinico Lozano Blesa" of Zaragoza
    Zaragoza, Spain
09

References and documents

Publications

  • Kader R, Hassan C, Lanas A, Romanczyk M, Romanczyk T, Kotowski B, Homedes CS, Mangiavillano B, Bonanno G, Lovat LB, Kaminski M, Faiss S, Repici A. A novel cloud-based artificial intelligence for real-time detection of colorectal neoplasia - a randomized controlled trial (EAGLE). NPJ Digit Med. 2025 Dec 26;9(1):84. doi: 10.1038/s41746-025-02270-1. PubMed 41449203 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Nov 2023, 6 months.

Results were first posted in Oct 2026, 2 years 11 months after primary completion.

Of 58 industry-sponsored interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 37. This study's 6 months is below that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2023
First posted
Feb 15, 2023
StartActual
May 10, 2023
Primary completionActual
Nov 20, 2023
CompletionActual
Nov 29, 2023
Results first posted
Oct 26, 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 26, 2026
Sites
1 site removed; no longer in Georgia
Show 1 removed
  • Israeli-Georgian Medical Research Clinic Healthycore · Tbilisi, Georgia
Oct 26, 2026
Interventions
Changed CADDIE→Colonoscopy with CADDIE. Added Procedure: Standard Colonoscopy
Oct 26, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedNumber of Adenoma per colonoscopyPer Colonoscopy (APC)Time frame: During the procedure/surgery → During the procedure
  • EditedPositive percent agreementPercent Agreement (PPA)Time frame: During the procedure/surgery → During the procedure
Oct 26, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41449203 ↗
Oct 26, 2026
Secondary outcomes
8 added
What changed in the outcomes
  • AddedAdenoma Detection Rate (ADR)Time frame: During procedure
  • AddedSessile Serrated Adenomas Per Colonoscopy (SSAPC)Time frame: During procedure
  • AddedSessile Serrated Adenomas Per Colonoscopy* (SSAPC*)Time frame: During procedure
  • AddedNeoplastic Polyps Per Colonoscopy (NPPC)Time frame: During procedure
  • AddedLarge Polyps Per Colonoscopy (PPC)Time frame: During procedure
  • AddedLarge Adenoma Per ColonoscopyTime frame: During the procedure
  • AddedColonoscope Withdrawal Time of Negative ProceduresTime frame: During procedure
  • AddedColonoscope Withdrawal TimeTime frame: During procedure
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41449203 ↗
    1 site removed; no longer in Georgia
    Show 1 removed
    • Israeli-Georgian Medical Research Clinic Healthycore · Tbilisi, Georgia
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedNumber of Adenoma per colonoscopyPer Colonoscopy (APC)Time frame: During the procedure/surgery → During the procedure
    • EditedPositive percent agreementPercent Agreement (PPA)Time frame: During the procedure/surgery → During the procedure
    Secondary outcomes 8 added
    What changed in the outcomes
    • AddedAdenoma Detection Rate (ADR)Time frame: During procedure
    • AddedSessile Serrated Adenomas Per Colonoscopy (SSAPC)Time frame: During procedure
    • AddedSessile Serrated Adenomas Per Colonoscopy* (SSAPC*)Time frame: During procedure
    • AddedNeoplastic Polyps Per Colonoscopy (NPPC)Time frame: During procedure
    • AddedLarge Polyps Per Colonoscopy (PPC)Time frame: During procedure
    • AddedLarge Adenoma Per ColonoscopyTime frame: During the procedure
    • AddedColonoscope Withdrawal Time of Negative ProceduresTime frame: During procedure
    • AddedColonoscope Withdrawal TimeTime frame: During procedure
    Interventions Changed CADDIE→Colonoscopy with CADDIE. Added Procedure: Standard Colonoscopy
    + 4 other changes: verification date, oversight details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05730192
Lead sponsor
Odin Medical
Collaborators
Meditrial Europe Ltd.
Responsible party
Sponsor
First posted
Feb 15, 2023
Start date
May 10, 2023
Primary completion
Nov 20, 2023
Completion
Nov 29, 2023
Results posted
Oct 26, 2026
Last update
Oct 26, 2026

Study contacts

Alessandro Repici, Prof.
principal investigator · Humanitas Research Hospital IRCCS, Rozzano-Milan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion